Motive Wealth Advisors Sells 29 Shares of Eli Lilly and Company (NYSE:LLY)

Motive Wealth Advisors lessened its stake in Eli Lilly and Company (NYSE:LLY) by 3.3% in the first quarter, Holdings Channel.com reports. The institutional investor owned 845 shares of the company’s stock after selling 29 shares during the quarter. Motive Wealth Advisors’ holdings in Eli Lilly and Company were worth $698,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of the stock. Grant Private Wealth Management Inc grew its stake in Eli Lilly and Company by 120.3% in the 1st quarter. Grant Private Wealth Management Inc now owns 859 shares of the company’s stock worth $709,000 after buying an additional 469 shares in the last quarter. Wealth Enhancement Advisory Services LLC grew its stake in Eli Lilly and Company by 11.3% in the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 151,865 shares of the company’s stock worth $125,425,000 after buying an additional 15,393 shares in the last quarter. Tritonpoint Wealth LLC grew its stake in Eli Lilly and Company by 1.7% in the 1st quarter. Tritonpoint Wealth LLC now owns 4,254 shares of the company’s stock worth $3,513,000 after buying an additional 70 shares in the last quarter. Stock Yards Bank & Trust Co. grew its stake in Eli Lilly and Company by 0.5% in the 1st quarter. Stock Yards Bank & Trust Co. now owns 110,957 shares of the company’s stock worth $91,641,000 after buying an additional 581 shares in the last quarter. Finally, Azzad Asset Management Inc. ADV purchased a new stake in shares of Eli Lilly and Company in the 1st quarter valued at $3,909,000. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on LLY shares. The Goldman Sachs Group raised shares of Eli Lilly and Company from a “neutral” rating to a “buy” rating and cut their price objective for the company from $892.00 to $888.00 in a research note on Tuesday, April 8th. Erste Group Bank lowered shares of Eli Lilly and Company from a “buy” rating to a “hold” rating in a report on Thursday, June 5th. Guggenheim reissued a “buy” rating on shares of Eli Lilly and Company in a research report on Friday, May 23rd. Morgan Stanley reissued an “overweight” rating on shares of Eli Lilly and Company in a research report on Thursday, May 1st. Finally, Cantor Fitzgerald initiated coverage on shares of Eli Lilly and Company in a research report on Tuesday, April 22nd. They set an “overweight” rating and a $975.00 price target for the company. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and eighteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Eli Lilly and Company presently has an average rating of “Moderate Buy” and an average price target of $1,011.37.

Eli Lilly and Company Stock Up 0.8%

Shares of Eli Lilly and Company stock opened at $818.56 on Friday. The company has a debt-to-equity ratio of 2.00, a current ratio of 1.15 and a quick ratio of 0.97. The company has a 50-day moving average of $775.43 and a 200 day moving average of $801.59. The firm has a market cap of $775.78 billion, a price-to-earnings ratio of 69.90, a PEG ratio of 1.40 and a beta of 0.41. Eli Lilly and Company has a 1 year low of $677.09 and a 1 year high of $972.53.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Thursday, May 1st. The company reported $3.34 earnings per share for the quarter, missing analysts’ consensus estimates of $4.64 by ($1.30). The firm had revenue of $12.73 billion for the quarter, compared to the consensus estimate of $12.77 billion. Eli Lilly and Company had a net margin of 23.51% and a return on equity of 85.24%. The firm’s revenue for the quarter was up 45.2% compared to the same quarter last year. During the same quarter in the prior year, the business posted $2.58 earnings per share. As a group, sell-side analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, June 10th. Shareholders of record on Friday, May 16th were paid a dividend of $1.50 per share. The ex-dividend date of this dividend was Friday, May 16th. This represents a $6.00 dividend on an annualized basis and a yield of 0.73%. Eli Lilly and Company’s dividend payout ratio is currently 48.82%.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.